What is NRIX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.32B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NRIX?

P/E (TTM) is n/a and 52-week range is $9.00 to $28.23 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NRIX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NRIX?

The company profile lists revenue (TTM) near $34M, net income (TTM) near $-31.89B, EPS (TTM) near $-3.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Nurix Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Brisbane California, California, US, 103.8M shares outstanding, ISIN US67080M1036 when available from company profile and filing metadata.

Nurix Therapeutics Inc

$NRIX

Health Care · Biotechnology

IR Run Scenarios

$22.35

+0.63%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Employees

317

Website

www.nurixtx.com/

IPO

2020-07-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)